[1] |
Hamilton G, Gillingwater TH. Spinal muscular atrophy: going beyond the motor neuron[J]. Trends Mol Med, 2013, 19(1): 40-50.
doi: 10.1016/j.molmed.2012.11.002
pmid: 23228902
|
[2] |
Verhaart IEC, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review[J]. Orphanet J Rare Dis, 2017, 12(1): 124.
doi: 10.1186/s13023-017-0671-8
pmid: 28676062
|
[3] |
Monani UR, Lorson CL, Parsons DW, et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2[J]. Hum Mol Genet, 1999, 8(7): 1177-1183.
pmid: 10369862
|
[4] |
Wirth B, Garbes L, Riessland M. How genetic modifiers influence the phenotype of spinal muscular atrophy and suggest future therapeutic approaches[J]. Curr Opin Genet Dev, 2013, 23(3): 330-338.
doi: 10.1016/j.gde.2013.03.003
|
[5] |
Wirth B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA)[J]. Hum Mutat, 2000, 15(3): 228-237.
pmid: 10679938
|
[6] |
Ogino S, Wilson RB. Genetic testing and risk assessment for spinal muscular atrophy (SMA)[J]. Hum Genet, 2002, 111(6): 477-500.
doi: 10.1007/s00439-002-0828-x
|
[7] |
Butcher S, Smith M, Woodcock IR, et al. False negative carrier screening in spinal muscular atrophy[J]. J Child Neurol, 2020, 35(4): 274-277.
doi: 10.1177/0883073819891269
pmid: 31858866
|
[8] |
Mercuri E, Finkel RS, Muntoni F, et al. Diagnosis and management of spinal muscular atrophy. Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care[J]. Neuromuscul Disord, 2018, 28(2): 103-115.
doi: 10.1016/j.nmd.2017.11.005
|
[9] |
Finkel RS, Mercuri E, Meyer OH, et al. Diagnosis and management of spinal muscular atrophy. Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics[J]. Neuromuscul Disord, 2018, 28: 197-207.
doi: 10.1016/j.nmd.2017.11.004
|
[10] |
北京医学会医学遗传学分会, 北京罕见病诊疗与保障学会. 脊髓性肌萎缩症遗传学诊断专家共识[J]. 中华医学杂志, 2020, 100(40): 3130-3140.
|
[11] |
Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy[J]. N Engl J Med, 2017, 377(18): 1723-1732.
doi: 10.1056/NEJMoa1702752
|
[12] |
Chan SH, Chae JH, Chien YH, et al. Nusinersen in spinal muscular atrophy type 1 from neonates to young adult: 1-year data from three Asia-Pacific regions[J]. J Neurol Neurosurg Psychiatry, 2021, 92(11): 1244-1246.
doi: 10.1136/jnnp-2020-324532
|
[13] |
Tsai CH, Jong YJ, Hu CJ, et al. Molecular analysis of SMN, NAIP and P44 genes of SMA patients and their families[J]. J Neurol Sci, 2001, 190(1-2): 35-40.
doi: 10.1016/s0022-510x(01)00574-3
pmid: 11574104
|
[14] |
Wang CC, Chang JG, Chen YL, et al. Multi-exon genotyping of SMN gene in spinal muscular atrophy by universal fluorescent PCR and capillary electrophoresis[J]. Electrophoresis, 2010, 31(14): 2396-2404.
doi: 10.1002/elps.v31:14
|
[15] |
Alías L, Barceló MJ, Bernal S, et al. Improving detection and genetic counseling in carriers of spinal muscular atrophy with two copies of the SMN1 gene[J]. Clin Genet, 2014, 85(5): 470-475.
doi: 10.1111/cge.12222
pmid: 23799925
|
[16] |
Ar Rochmah M, Awano H, Awaya T, et al. Spinal muscular atrophy carriers with two SMN1 copies[J]. Brain Dev, 2017, 39(10): 851-860.
doi: 10.1016/j.braindev.2017.06.002
|
[17] |
曹延延, 程苗苗, 宋昉, 等. 脊髓性肌萎缩症SMN1基因2+0基因型携带者的家系研究[J]. 遗传, 2021, 43(2): 160-168.
|